What type of study is this?

Grandchildren of GRNDaD: Shifts in disease‐modifying therapy at the adolescent transition in sickle cell disease

View Full Paper

Ask AI

Bookmark

Authors

Observational analysis highlights changes in disease-modifying therapy utilization in sickle cell patients, suggesting improvements in care.

A significant proportion of patients, about 65%, are on hydroxyurea for sickle cell disease treatment.
Chronic RBC transfusion rates were nearly double in the 18-29 age group compared to those aged 11-17 years.
The study examined the usage of novel therapeutics like Voxelotor and crizanlizumab, indicating increased utilization in comprehensive care.
Older age groups showed a lower proportion of patients on hydroxyurea, implying a shift in therapy preferences.

Chang et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Observational analysis highlights changes in disease-modifying therapy utilization in sickle cell patients, suggesting improvements in care.